BRPI0815659A2 - N- (ARYLAMINO) SULPHONAMIDE DERIVATIVES INCLUDING POLYMORPHS AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME - Google Patents

N- (ARYLAMINO) SULPHONAMIDE DERIVATIVES INCLUDING POLYMORPHS AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME

Info

Publication number: BRPI0815659A2
Authority: BR; Brazil
Prior art keywords: methods; arylamino; compositions; preparing; well
Prior art date: 2007-07-30

Application number

BRPI0815659-0A2A

Other languages

Portuguese (pt)

Inventor

Jean-Michel Vernier

Colin Edward Rowlings

Jean-Luc Girardet

Stuart Dimock

Barry Quart

Jeffrey N Miner

Original Assignee

Ardea Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-30

Filing date

2008-07-28

Publication date

2014-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0815659(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-07-30 Priority claimed from US11/830,733 external-priority patent/US8101799B2/en

2008-07-28 Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc

2014-09-30 Publication of BRPI0815659A2 publication Critical patent/BRPI0815659A2/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
- A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
- A01N41/04—Sulfonic acids; Derivatives thereof
- A01N41/06—Sulfonic acid amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Dentistry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Plant Pathology (AREA)
Rheumatology (AREA)
Wood Science & Technology (AREA)

BRPI0815659-0A2A 2007-07-30 2008-07-28 N- (ARYLAMINO) SULPHONAMIDE DERIVATIVES INCLUDING POLYMORPHS AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME BRPI0815659A2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US11/830,733 US8101799B2 (en)	2005-07-21	2007-07-30	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P	2008-03-06	2008-03-06
US3446608P	2008-03-06	2008-03-06
US4488608P	2008-04-14	2008-04-14
PCT/US2008/071392 WO2009018233A1 (en)	2007-07-30	2008-07-28	Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Publications (1)

Publication Number	Publication Date
BRPI0815659A2 true BRPI0815659A2 (en)	2014-09-30

Family

ID=40304796

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0815659-0A2A BRPI0815659A2 (en)	2007-07-30	2008-07-28	N- (ARYLAMINO) SULPHONAMIDE DERIVATIVES INCLUDING POLYMORPHS AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME

Country Status (22)

Country	Link
EP (1)	EP2184984A4 (en)
JP (3)	JP2010535232A (en)
KR (3)	KR20100092424A (en)
CN (2)	CN103479604B (en)
AP (1)	AP2817A (en)
AU (2)	AU2008282338B2 (en)
BR (1)	BRPI0815659A2 (en)
CA (1)	CA2693390C (en)
CO (1)	CO6470808A2 (en)
CR (1)	CR11244A (en)
DO (1)	DOP2010000045A (en)
EA (2)	EA032294B1 (en)
EC (1)	ECSP109910A (en)
HN (1)	HN2010000203A (en)
IL (1)	IL203296A (en)
MA (1)	MA31881B1 (en)
MX (1)	MX2010001244A (en)
NZ (1)	NZ582929A (en)
PH (1)	PH12015501914A1 (en)
SV (1)	SV2010003469A (en)
TN (1)	TN2010000049A1 (en)
WO (1)	WO2009018233A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7723477B2 (en)	2005-10-31	2010-05-25	Oncomed Pharmaceuticals, Inc.	Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN102131771A (en) *	2008-04-14	2011-07-20	阿迪生物科学公司	Compositions and methods for preparing and using same
BRPI0918526B1 (en) *	2008-09-09	2022-02-15	F. Hoffmann-La Roche Ag	POLYMORPHIC CRYSTALLINE FORM OF ACYL SULFONAMIDES, ITS PREPARATION PROCESS, USE AND PHARMACEUTICAL COMPOSITION THAT COMPRISES IT
NZ592338A (en)	2008-09-26	2012-11-30	Oncomed Pharm Inc	Frizzled-binding agents and uses thereof
SG174272A1 (en) *	2009-03-11	2011-10-28	Ardea Biosciences Inc	Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
UY32486A (en) *	2009-03-11	2010-10-29	Ardea Biosciences Inc	TREATMENT OF CANCER CANCER
ES2534358T3 (en)	2009-10-13	2015-04-21	Allomek Therapeutics, Llc	Innovative MEK inhibitors useful in the treatment of diseases
WO2011047788A1 (en) *	2009-10-21	2011-04-28	Bayer Schering Pharma Aktiengesellschaft	Substituted benzosulphonamides
TWI535445B (en)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Wnt antagonists and methods of treatment and screening
CN102020651B (en)	2010-11-02	2012-07-18	北京赛林泰医药技术有限公司	6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) *	2011-02-23	2012-08-29	苏州波锐生物医药科技有限公司	Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
EA201391587A1 (en) *	2011-04-28	2014-08-29	Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч	COMBINED THERAPY BASED ON HSP90
AR086553A1 (en) *	2011-05-27	2014-01-08	Bayer Ip Gmbh	CHIRAL SYNTHESIS OF N- {3,4-DIFLUORO-2 - [(2-FLUORO-4-IODOPHENYL) AMINO] -6-METOXIFENIL} -1- [2,3-DIHYDROXI-PROPIL] CYCLOPROPANE SULFONAMIDS
JP2015502958A (en) *	2011-12-09	2015-01-29	オンコメッドファーマシューティカルズインコーポレイテッド	Combination therapy for the treatment of cancer
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
BR112014029338A2 (en) *	2012-05-31	2017-06-27	Bayer Pharma AG	biomarkers for determining the effective response of hepatocellular carcinoma (hcc) treatment
MX348290B (en)	2012-06-04	2017-06-05	Pharmacyclics Llc	Crystalline forms of a bruton's tyrosine kinase inhibitor.
FI3702351T3 (en) *	2012-10-19	2024-01-24	Array Biopharma Inc	Formulation comprising a mek inhibitor
CA2890238A1 (en)	2012-11-02	2014-05-08	Merck Patent Gmbh	Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
JP2016510411A (en)	2013-02-04	2016-04-07	オンコメッドファーマシューティカルズインコーポレイテッド	Methods and monitoring of treatment with WNT pathway inhibitors
EP2848246A1 (en)	2013-09-13	2015-03-18	Bayer Pharma Aktiengesellschaft	Pharmaceutical compositions containing refametinib
EP3046557A1 (en)	2013-09-20	2016-07-27	Stichting Het Nederlands Kanker Instituut	Rock in combination with mapk-pathway
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
US20170114323A1 (en)	2014-06-19	2017-04-27	Whitehead Institute For Biomedical Research	Uses of kinase inhibitors for inducing and maintaining pluripotency
AU2015306683B2 (en)	2014-08-25	2021-11-25	Societe Des Produits Nestle S.A.	Egg protein formulations and methods of manufacture thereof
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of proton tyrosine kinase inhibitor
BR112019026483A2 (en) *	2017-06-16	2020-07-14	Beta Pharma, Inc.	pharmaceutical formulation of n- (2- (2- (dimethylamine) ethoxy) -4-methoxy-5 - ((4- (1-methyl-1h-indol-3-yl) pyrimidin-2-yl) amine) phenyl) acrylamide and its salts
CN114364798A (en)	2019-03-21	2022-04-15	欧恩科斯欧公司	Combination of Dbait molecules with kinase inhibitors for the treatment of cancer
JP2022551439A (en) *	2019-10-04	2022-12-09	スミトモファーマオンコロジー，インコーポレイテッド	AXL inhibitor formulation
JP2023500906A (en)	2019-11-08	2023-01-11	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	Methods of treating cancers with acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
US12371667B2 (en)	2021-05-13	2025-07-29	Washington University	Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma
CN118834328B (en) *	2024-07-02	2025-09-16	江苏海洋大学	Preparation method and application of metalloprotease 9 epitope imprinting nano-particles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162117A (en) *	1991-11-22	1992-11-10	Schering Corporation	Controlled release flutamide composition
JP2575590B2 (en) *	1992-07-31	1997-01-29	塩野義製薬株式会社	Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
ES2177868T3 (en) *	1992-08-25	2002-12-16	Searle & Co	HYDROXYETHYLAMINOSULPHONAMIDS OF ALPHA- AND BETA-AMINO ACIDS AS INHIBITORS OF RETROVIRIC PROTEASES.
US7115632B1 (en) *	1999-05-12	2006-10-03	G. D. Searle & Co.	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
ES2249060T3 (en) *	1999-01-13	2006-03-16	Warner-Lambert Company Llc	DIARILAMINS REPLACED WITH 1-HETEROCICLE.
GB0003224D0 (en) *	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
US7235567B2 (en) *	2000-06-15	2007-06-26	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
WO2003026574A2 (en) *	2001-09-24	2003-04-03	Au Jessie L-S	Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
EP1534262A1 (en) *	2002-07-17	2005-06-01	Titan Pharmaceuticals, Inc.	Combination of chemotherapeutic drugs for increasing antitumor activity
ES2369535T3 (en) *	2002-07-30	2011-12-01	Eterna Zentaris Gmbh	USE OF ALQUILFOSFOCOLINAS IN COMBINATION WITH ANTITUMORAL MEDICINES.
WO2006110811A1 (en) *	2005-04-12	2006-10-19	Elan Pharma International Limited	Nanoparticulate quinazoline derivative formulations
CN101198582A (en) *	2005-04-22	2008-06-11	橘生药品工业株式会社	Polymorphic crystal of 4'-{2-[ (1s, 2r) - 2- hydroxy -2- (4-hydroxyphenyl) -1- methylethylamino] ethoxy} - 3 - isopropyl-3', 5' -dimethylbiphenyl - 4 - carboxylic acid hydrochloride
ES2481402T3 (en) *	2005-07-21	2014-07-30	Ardea Biosciences, Inc.	MEK N- (arylamino) sulfonamide inhibitors
JP2007099763A (en) *	2005-09-08	2007-04-19	Toyama Chem Co Ltd	Novel crystals of piperacillin sodium monohydrate and process for producing the same
TW200800150A (en) *	2005-12-21	2008-01-01	Organon Nv	Compounds with medicinal effects due to interaction with the glucocorticoid receptor

2008
- 2008-07-28 CN CN201310317815.8A patent/CN103479604B/en not_active Expired - Fee Related
- 2008-07-28 KR KR1020107004742A patent/KR20100092424A/en not_active Ceased
- 2008-07-28 AU AU2008282338A patent/AU2008282338B2/en not_active Ceased
- 2008-07-28 BR BRPI0815659-0A2A patent/BRPI0815659A2/en not_active Application Discontinuation
- 2008-07-28 KR KR1020157020493A patent/KR20150091434A/en not_active Ceased
- 2008-07-28 WO PCT/US2008/071392 patent/WO2009018233A1/en not_active Ceased
- 2008-07-28 CN CN2008801088296A patent/CN101808516B/en not_active Expired - Fee Related
- 2008-07-28 EP EP08796733.7A patent/EP2184984A4/en not_active Ceased
- 2008-07-28 AP AP2010005134A patent/AP2817A/en active
- 2008-07-28 NZ NZ582929A patent/NZ582929A/en not_active IP Right Cessation
- 2008-07-28 CA CA2693390A patent/CA2693390C/en not_active Expired - Fee Related
- 2008-07-28 EA EA201400552A patent/EA032294B1/en not_active IP Right Cessation
- 2008-07-28 JP JP2010520118A patent/JP2010535232A/en active Pending
- 2008-07-28 KR KR1020147017261A patent/KR20140098185A/en not_active Ceased
- 2008-07-28 MX MX2010001244A patent/MX2010001244A/en active IP Right Grant
- 2008-07-28 EA EA201000268A patent/EA020624B1/en not_active IP Right Cessation
2010
- 2010-01-13 IL IL203296A patent/IL203296A/en not_active IP Right Cessation
- 2010-01-29 CO CO10009526A patent/CO6470808A2/en not_active Application Discontinuation
- 2010-01-29 HN HN2010000203A patent/HN2010000203A/en unknown
- 2010-01-29 CR CR11244A patent/CR11244A/en not_active Application Discontinuation
- 2010-01-29 DO DO2010000045A patent/DOP2010000045A/en unknown
- 2010-01-29 SV SV2010003469A patent/SV2010003469A/en unknown
- 2010-01-29 EC EC2010009910A patent/ECSP109910A/en unknown
- 2010-01-29 TN TNP2010000049A patent/TN2010000049A1/en unknown
- 2010-02-19 MA MA32636A patent/MA31881B1/en unknown
2014
- 2014-11-14 JP JP2014231450A patent/JP6309880B2/en not_active Expired - Fee Related
2015
- 2015-01-28 AU AU2015200390A patent/AU2015200390B2/en not_active Ceased
- 2015-08-28 PH PH12015501914A patent/PH12015501914A1/en unknown
2017
- 2017-02-03 JP JP2017018477A patent/JP2017125021A/en active Pending

Also Published As

Publication number	Publication date
CA2693390C (en)	2017-01-17
KR20140098185A (en)	2014-08-07
KR20150091434A (en)	2015-08-10
CR11244A (en)	2010-05-20
ECSP109910A (en)	2010-04-30
AU2008282338A1 (en)	2009-02-05
EP2184984A4 (en)	2013-07-24
AU2008282338B2 (en)	2015-02-12
CO6470808A2 (en)	2012-06-29
NZ582929A (en)	2012-03-30
CN103479604B (en)	2016-08-10
EP2184984A1 (en)	2010-05-19
AP2817A (en)	2013-12-31
KR20100092424A (en)	2010-08-20
SV2010003469A (en)	2010-04-30
JP2017125021A (en)	2017-07-20
MA31881B1 (en)	2010-12-01
HN2010000203A (en)	2012-11-19
AP2010005134A0 (en)	2010-02-28
EA201000268A1 (en)	2010-08-30
MX2010001244A (en)	2010-08-31
EA032294B1 (en)	2019-05-31
EA201400552A1 (en)	2014-09-30
JP2015078199A (en)	2015-04-23
PH12015501914A1 (en)	2017-07-31
CN101808516B (en)	2013-08-28
CN101808516A (en)	2010-08-18
CN103479604A (en)	2014-01-01
JP6309880B2 (en)	2018-04-11
WO2009018233A1 (en)	2009-02-05
TN2010000049A1 (en)	2011-09-26
DOP2010000045A (en)	2010-10-31
HK1147396A1 (en)	2011-08-12
CA2693390A1 (en)	2009-02-05
JP2010535232A (en)	2010-11-18
AU2015200390B2 (en)	2017-02-23
IL203296A (en)	2017-06-29
EA020624B1 (en)	2014-12-30

Publication	Publication Date	Title
BRPI0815659A2 (en)	2014-09-30	N- (ARYLAMINO) SULPHONAMIDE DERIVATIVES INCLUDING POLYMORPHS AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME
AU2015200390A1 (en)	2015-02-19	Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
BRPI0822104A2 (en)	2014-10-07	ANTIMICROBIAN COMPOSITIONS AND METHODS FOR THE USE OF THE SAME
BRPI0813237A2 (en)	2014-12-23	COMPOUND, METHOD FOR PREPARING COMPOUND, COMPOSITION, MEDICINE, AND, USE OF COMPOUND.
BRPI0818003A2 (en)	2019-09-24	csf-1r inhibitors, compositions and methods of use
BRPI1010775A2 (en)	2016-03-22	composition, method for preparing a composition, and use of a composition.
BRPI0920263A2 (en)	2016-07-12	compound, use of compound, composition, and method
UY33132A (en)	2011-07-29	SOLUBLE PROTEINS FOR THERAPEUTIC USE
BRPI0813627A2 (en)	2014-12-23	ANTIMICROBIAN PEPTIDIA, COMPOSITIONS AND METHODS OF USE
BRPI0918359A2 (en)	2015-12-15	compound, agrochemical composition, use of agrochemical composition and method for preparation of compound
CR10743A (en)	2009-06-05	DERIVATIVES OF AZAADAMANTANO AND METHODS OF USE OF THE SAME
BRPI0812159A2 (en)	2017-05-02	csf-1r inhibitors, compositions and methods of use
ECSP109856A (en)	2010-02-26	DERIVATIVES OF OXADIAZOL AND ITS USE AS POTENTIALS OF METABOTROPIC RECEIVERS OF GLUTAMATE - 842
BRPI0911297A2 (en)	2019-09-24	composition and methods for preparation and use thereof
DK2344486T3 (en)	2013-07-08	Alkylthiazole carbamate derivatives, their preparation and their use as inhibitors of the enzyme FAAH
BRPI0818459A2 (en)	2015-04-14	Pharmaceutical composition suitable for ophthalmic use.
BR112012001998A2 (en)	2017-01-31	ophthalmic solution, use of a compound, and method for preparing an ophthalmic solution.
BRPI0812909A2 (en)	2014-12-09	POLICYCLIC GUANINE DERIVATIVES AND METHODS OF USE THEREOF.
BRPI0923513A2 (en)	2016-01-26	method and compositions for use of a coccidiosis vaccine
BRPI0808172A2 (en)	2014-11-04	Heterocyclic Compounds, Understanding Compositions, and Methods of Use.
BRPI0910179A2 (en)	2016-01-19	amine compound, pharmaceutical composition and use of amine compound
BRPI0808813A2 (en)	2016-08-02	method for the preparation of rubber compounds, and use of compounds
BR112012004173A2 (en)	2017-05-30	"compound, composition, method for preparing a composition, and use of a compound"
BRPI0920862A2 (en)	2015-12-22	composition, method of manufacture, and use thereof
BRPI0812166A2 (en)	2015-07-07	Compositions useful for reducing nephrotoxicity and methods of use thereof

Legal Events

Date	Code	Title	Description
2016-02-23	B25G	Requested change of headquarter approved	Owner name: ARDEA BIOSCIENCES, INC. (US)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-21	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2020-03-31	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-09-08	B09B	Patent application refused [chapter 9.2 patent gazette]
2020-11-24	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL